Xalud Therapeutics is a gene therapy platform that addresses chronic pain. The lead product candidate, XT-150 is in two P2 clinical studies for the treatment of Osteoarthritis Pain. Xalud is a portfolio company of PBM Capital Group.
Xalud Therapeutics, Inc. is developing novel therapies for the treatment of neuro-inflammatory diseases. Xalud is also developing treatments for inflammatory joint disorders including osteoarthritis and rheumatoid arthritis.
Xalud welcomes inquiries regarding development partnerships, investment and scientific collaboration. Please contact us if you are interested in learning more about Xalud. We look forward to speaking with you.